Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms

Angelo B. A. Laranjeira, Tim Kong, Steven Craig Snyder, Mary C. Fulbright, Daniel A.C. Fisher, Daniel T. Starczynowski, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 991.

https://doi.org/10.1182/blood-2023-182290

Published: 2023

Journal Articles

RSK1 Is an Exploitable Dependency in Myeloid Malignancies

Tim Kong, Angelo B. A. Laranjeira, LaYow Yu, Jared Scott Fowles, Daniel A.C. Fisher, Sherwin Ng, Wei Yang, Fan He, Maggie J Cox, Mary C. Fulbright, Stacey L. Rentschler, My-my Huynh, Gerrit Los, Sandra E. Dunn, Grant A Challen, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 46.

https://doi.org/10.1182/blood-2023-182320

Published: 2023

Journal Articles

Galectin-1 Fuels Monocyte-Driven Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

Fan He, Tim Kong, Shuyang Lin, Mary C. Fulbright, Angelo B. A. Laranjeira, Daniel A.C. Fisher, Maggie J Cox, Katrina Ashworth, Jorge Di Paola, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 4518.

https://doi.org/10.1182/blood-2023-189252

Published: 2023

Journal Articles

Leukemic Driver Clones Can Arise Independently and Outcompete MPN Cells in Post-MPN Secondary AML

Tyler M Parsons, Andrew L Young, Daniel A.C. Fisher, Maggie J Cox, Stephen T. Oh, Grant A Challen

Blood (2023) 142 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2023-186610

Published: 2023

Journal Articles

Imaging Mass Cytometry Reveals the Spatial Architecture of Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemias

Karolyn A. Oetjen, MDPhD, Diane E. Bender, PhD, Marianna B. Ruzinova, MDPhD, Daniel A.C. Fisher, PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142238

Published: 2020

Journal Articles

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Amy Zhou, MD, Stephen T. Oh, MD

Blood (2019) 134 (Supplement_1): 4210.

https://doi.org/10.1182/blood-2019-131128

Published: 2019

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

Journal Articles

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

Amy Zhou, MD, Maggie J. Allen, Mary Fulbright, Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2018-99-113661

Published: 2018

Journal Articles

Mass Cytometry Analysis Reveals Cellular Loci of Cytokine Overproduction in Myelofibrosis with Differential Sensitivity to Ruxolitinib

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Taylor B. Collins, Hengrui Hu, Olga Malkova, Stephen Oh, MD PhD

Blood (2017) 130 (Supplement 1): 4209.

https://doi.org/10.1182/blood.V130.Suppl_1.4209.4209

Published: 2017

Journal Articles

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Stephen T. Oh, MD PhD, Christopher A. Miller, PhD, Yevgeniy Gindin, PhD, Taylor M. Brost, Jason Chan, MD PhD, Mary C. Fulbright, Daniel A.C. Fisher, PhD, Eric J. Duncavage, MD, Michelle O'Laughlin, Malachi Griffith, PhD, Obi L. Griffith, PhD, Lukas D. Wartman, MD

Blood (2016) 128 (22): 5496.

https://doi.org/10.1182/blood.V128.22.5496.5496

Published: 2016

Journal Articles

Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis

Daniel A.C. Fisher, PhD, Cathrine A. Miner, Elizabeth K. Engle, PhD, Taylor M. Brost, Olga Malkova, Stephen T. Oh, MD PhD

Blood (2016) 128 (22): 4277.

https://doi.org/10.1182/blood.V128.22.4277.4277

Published: 2016

Journal Articles

Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry

Shovik Bandyopadhyay, Liyang Yu, Daniel A.C. Fisher, PhD, Olga Malkova, Stephen T. Oh, MD PhD

Blood (2016) 128 (22): 4278.

https://doi.org/10.1182/blood.V128.22.4278.4278

Published: 2016

Journal Articles

NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Elizabeth K. Engle, PhD, Olga Malkova, PhD, Mary C. Fulbright, Amy Zhou, MD, Stephen Oh, MDPhD

Blood (2015) 126 (23): 602.

https://doi.org/10.1182/blood.V126.23.602.602

Published: 2015

Journal Articles

Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms

Daniel A.C. Fisher, PhD, Olga Malkova, Mary C. Fulbright, Gregory K. Behbehani, MD PhD, Garry P. Nolan, PhD, Stephen T. Oh, MD PhD

Blood (2014) 124 (21): 1884.

https://doi.org/10.1182/blood.V124.21.1884.1884

Published: 2014

Journal Articles

Mass Cytometry Analysis Of Myelofibrosis and Secondary Acute Myeloid Leukemia Reveals Constitutive and Cytokine Induced Signaling Abnormalities With Differential Sensitivities To Ruxolitinib

Daniel A.C. Fisher, PhD, Gregory K. Behbehani, MD, PhD, Garry P. Nolan, PhD, Sean C. Bendall, PhD, Stephen T. Oh, MD, PhD

Blood (2013) 122 (21): 1610.

https://doi.org/10.1182/blood.V122.21.1610.1610

Published: 2013

Journal Articles

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL -Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Eric M. Knoche, MD, Daniel A.C. Fisher, PhD, Gregory Rippberger, Li He, MS, BS, Deborah M. Moore, Jonathan L. Klein, MD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 2832.

https://doi.org/10.1182/blood.V120.21.2832.2832

Published: 2012

Journal Articles

Single Cell Mass Cytometry of Dysregulated Signaling Networks in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Erin F. Simonds, PhD, Gregory K. Behbehani, MD, PhD, Garry P. Nolan, PhD, Sean C. Bendall, PhD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 703.

https://doi.org/10.1182/blood.V120.21.703.703

Published: 2012

Journal Articles

Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Christopher A. Miller, Michael D. McLellan, Robert S. Fulton, Katherine L. Martin, Charu Kaiwar, Deborah M. Moore, Timothy J. Ley, MD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 706.

https://doi.org/10.1182/blood.V120.21.706.706

Published: 2012

NARROW

In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms

RSK1 Is an Exploitable Dependency in Myeloid Malignancies

Galectin-1 Fuels Monocyte-Driven Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

Leukemic Driver Clones Can Arise Independently and Outcompete MPN Cells in Post-MPN Secondary AML

Imaging Mass Cytometry Reveals the Spatial Architecture of Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemias

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

Mass Cytometry Analysis Reveals Cellular Loci of Cytokine Overproduction in Myelofibrosis with Differential Sensitivity to Ruxolitinib

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis

Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry

NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia

Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms

Mass Cytometry Analysis Of Myelofibrosis and Secondary Acute Myeloid Leukemia Reveals Constitutive and Cytokine Induced Signaling Abnormalities With Differential Sensitivities To Ruxolitinib

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL -Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Single Cell Mass Cytometry of Dysregulated Signaling Networks in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only